Canada markets closed
  • S&P/TSX

    19,472.74
    +181.74 (+0.94%)
     
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • DOW

    34,777.76
    +229.26 (+0.66%)
     
  • CAD/USD

    0.8246
    +0.0018 (+0.22%)
     
  • CRUDE OIL

    64.82
    -0.08 (-0.12%)
     
  • BTC-CAD

    70,443.08
    -1,301.12 (-1.81%)
     
  • CMC Crypto 200

    1,480.07
    +44.29 (+3.08%)
     
  • GOLD FUTURES

    1,832.00
    +0.70 (+0.04%)
     
  • RUSSELL 2000

    2,271.63
    +30.21 (+1.35%)
     
  • 10-Yr Bond

    1.5770
    +0.0160 (+1.02%)
     
  • NASDAQ

    13,752.24
    +119.44 (+0.88%)
     
  • VOLATILITY

    16.69
    -1.70 (-9.24%)
     
  • FTSE

    7,129.71
    +53.54 (+0.76%)
     
  • NIKKEI 225

    29,357.82
    +26.42 (+0.09%)
     
  • CAD/EUR

    0.6772
    -0.0045 (-0.66%)
     

Stocks in play: PharmaTher Holdings Ltd.

  • Oops!
    Something went wrong.
    Please try again later.
Baystreet.ca
  • Oops!
    Something went wrong.
    Please try again later.

Announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining the novel use of ketamine as a potential treatment for Type 2 diabetes and obesity, based on the evaluation of the Company’s drug repurposing artificial intelligence (“AI”) platform, panaceAI™. PharmaTher is also advancing research with panaceAI™ to evaluate repurposing opportunities with N,N-Dimethyltryptamine (“DMT”), 3,4-Methylenedioxy methamphetamine (“MDMA”) and lysergic acid diethylamide (“LSD”) for future clinical development and partnering opportunities. PharmaTher Holdings Ltd. shares C.PHRM are trading unchanged at $0.24.

Read: